Skip to main content

Teclistamab News

Tecvayli (teclistamab-cqyv) Biweekly Dosing Approved by the U.S. FDA for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

HORSHAM, Pa., Feb. 20, 2024 /PRNewswire/ – Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ...

FDA Approves Tecvayli (teclistamab-cqyv) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Tecvayli, an off-the-shelf, subcutaneous therapy, is an important new medicine for patients with incurable blood cancer who face limited treatment options HORSHAM, Pa., October 25, 2022 – The J...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related condition support groups

Multiple Myeloma

Teclistamab patient information at Drugs.com